1888305-17-6

1888305-17-6 structure
1888305-17-6 structure
  • Name: ERK5-IN-4
  • Chemical Name: ERK5-IN-4
  • CAS Number: 1888305-17-6
  • Molecular Formula: C16H11Cl2FN4O2
  • Molecular Weight: 381.19
  • Catalog: Signaling Pathways MAPK/ERK Pathway ERK
  • Create Date: 2022-09-08 19:47:06
  • Modify Date: 2024-01-09 12:58:34
  • ERK5-IN-4 (compound 34b) is a potent and selective inhibitor of extracellular signal-related kinase 5 (ERK5). ERK5-IN-4 inhibits ERK5 (full-length) and truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with an IC50 of 77 nM and 300 nM, respectively[1].

Name ERK5-IN-4
Description ERK5-IN-4 (compound 34b) is a potent and selective inhibitor of extracellular signal-related kinase 5 (ERK5). ERK5-IN-4 inhibits ERK5 (full-length) and truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with an IC50 of 77 nM and 300 nM, respectively[1].
Related Catalog
Target

ERK5

In Vitro ERK5-IN-4 (compound 34b) is selective against MAP3K, p38 (IC50>30 μM) and BRD4 (IC50>20 μM), in contrast to many reported ERK5 inhibitors[1]. ERK5-IN-4 (0-100 μM; 72 h) suppresses ERK5 kinase activity in HEK293 cells and (0-1 μM; 72 h) induces paradoxical activation of ERK5 transcriptional activity, thus resulting in C-terminal transcriptional activation domain (TAD) separated from the nuclear localization sequence (NLS) and results ERK5 nuclear translocation[1]. ERK5-IN-4 inhibits cancer cells with GI50 of 19.6 μM (HEK293), 22.3 μM (A498), 25 μM (SJSA-1), 26.6 μM (MDA-MB-231) following a 72 h incubation[1]. ERK5-IN-4 exhibits kinome selectivity Kd of 1.2 μM, 0.29 μM, 0.046 μM, 0.061 μM, 0.18 μM, 0.38 μM, 1.3 μM, 0.42 μM, 0.22 μM, 2.8 μM against ABL1-nonphosphorylated, AURKA, CSF1R, DCAMKL1 (DCLK1), ERK5 (MAPK7), FGFR1, JAK3 (JH1domain-catalytic), KIT, LRRK2, MEK5 (MAP2K5)[1]. Western Blot Analysis[1] Cell Line: HeLa cells Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM Incubation Time: 1 h Result: Resulted upper phospho-ERK5 band with EGF stimulation and inhibition.
In Vivo ERK5-IN-4 (compound 34b) (p.o.; 10 mg/kg) has low clearance and an oral bioavailability of 42% in the mouse[1]. Animal Model: Pharmacokinetic Parameters for ERK5-IN-4[1] Dosage: Administration: Result: Route Dose (mg/kg) Cl (mL/min/kg) Vd (L/kg) t1/2 (min) BA (%) i.v. or p.o. 10 14 0.6 80 42
References

[1]. Miller DC, et al. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. J Med Chem. 2022 May 12. 65(9):6513-6540.

Molecular Formula C16H11Cl2FN4O2
Molecular Weight 381.19
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.